HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Clinical trials for HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC explained in plain language.
Never miss a new study
Get alerted when new HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC trials appear
Sign up with your email to follow new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Race against time: can more frequent radiation beat back cancer recurrence?
Disease control Recruiting nowThis study is for people with head and neck cancer who have had surgery and need follow-up radiation, but are starting that radiation more than 6 weeks later. It aims to find out if getting radiation 6 days a week is more effective at preventing the cancer from coming back than t…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
AI-Designed drug trial seeks to shrink tough cancers
Disease control Recruiting nowThis study is testing a new drug called GTAEXS617 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors in cancers like head & neck, lung, pancreatic, ovarian, and bre…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE1, PHASE2 • Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New drug trial opens for patients with advanced cancers
Disease control Recruiting nowThis is an early-stage study testing a new drug called MT-4561 in people with various advanced solid tumors who have run out of standard treatment options. The main goals are to find a safe dose, see how the body processes the drug, and check for any early signs that it might hel…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE1, PHASE2 • Sponsor: Tanabe Pharma America, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New Two-Drug attack on tough head and neck cancers
Disease control Recruiting nowThis study is testing whether adding an experimental drug called fianlimab to an existing cancer drug (cemiplimab) works better for treating advanced head and neck cancer that has returned or spread. It will involve about 120 people whose cancer has not been treated for its advan…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New Two-Drug attack tested to shrink tumors before cancer surgery
Disease control Recruiting nowThis study is testing whether giving two drugs—ficerafusp alfa (an experimental drug) and pembrolizumab (an approved immunotherapy)—before surgery can help shrink tumors and improve outcomes for people with high-risk, operable head and neck cancer. The goal is to see if this pre-…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New weapon tested against tough cancers that have stopped responding
Disease control Recruiting nowThis is a first-in-human study to test the safety and early signs of effectiveness of a new drug called STRO-004 in adults with advanced solid tumors that have come back or stopped responding to other treatments. The trial will test STRO-004 alone and in combination with an exist…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE1 • Sponsor: Sutro Biopharma, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Cancer trial aims to cut harsh radiation, spare Patients' side effects
Disease control Recruiting nowThis study is for people with advanced head and neck cancer who have already had surgery and a strong response to drug treatments. Researchers want to see if they can safely give less radiation therapy to the neck after surgery. The goal is to see if this lower dose still control…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: NA • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC
-
New pill targets tough cancers after other treatments fail
Disease control Recruiting nowThis early-stage study is testing a new oral drug called VMD-928, both by itself and combined with an existing immunotherapy (pembrolizumab). It is for adults with advanced solid tumors or lymphoma that have progressed despite available treatments. The main goals are to find safe…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE1, PHASE2 • Sponsor: VM Oncology, LLC • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
First patients to receive new cancer drug in groundbreaking safety trial
Disease control Recruiting nowThis is the first-ever study in people for a new drug called EPI-326. It aims to find a safe dose and see how the body handles the drug in patients with advanced lung cancer (with a specific genetic change called EGFR mutation) or advanced head and neck cancer. The main goal is t…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE1 • Sponsor: EpiBiologics • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New drug duo aims to shrink tumors before cancer surgery
Disease control Recruiting nowThis early-stage study is testing a new two-drug combination (GV20-0251 plus sintilimab) given to patients before surgery for head and neck cancer. The main goals are to find a safe dose and see if the treatment can shrink the tumors, which is measured by examining the tissue rem…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
New drug cocktails aim to shrink tumors before cancer surgery
Disease control Recruiting nowThis study tests whether giving one or two immunotherapy drugs before surgery is safe and can help shrink tumors in people with operable head and neck cancer. About 80 patients will receive either nivolumab alone or combined with another drug (relatlimab or ipilimumab) for a few …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE2 • Sponsor: Dan Zandberg • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
New cancer drug combo trial seeks to control advanced tumors
Disease control Recruiting nowThis study is testing a new drug called XL092, both by itself and in combination with other immunotherapy drugs, for people with advanced solid tumors that cannot be removed by surgery. The main goals are to find safe doses and see if the treatments can shrink tumors or slow thei…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE1 • Sponsor: Exelixis • Aim: Disease control
Last updated Mar 20, 2026 14:47 UTC
-
First patients to test new cancer drug in hopes of controlling advanced tumors
Disease control Recruiting nowThis is the first study in people to test a new drug called LB-LR1109. The main goal is to find a safe and tolerable dose for patients with advanced or metastatic solid tumors, including lung, head and neck, kidney, bladder cancers, and melanoma. The study will test the drug alon…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE1 • Sponsor: LG Chem • Aim: Disease control
Last updated Mar 09, 2026 14:25 UTC
-
Phone app aims to help cancer patients keep weight on during treatment
Symptom relief Recruiting nowThis study tests whether using a smartphone app to track symptoms helps patients with head and neck cancer maintain their weight during curative radiation or chemo-radiation treatment. Researchers want to see if catching problems early through remote monitoring leads to less weig…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: NA • Sponsor: Centre Henri Becquerel • Aim: Symptom relief
Last updated Mar 30, 2026 14:34 UTC
-
Scientists collect cancer patients' cells for future 'living drug' therapy
Knowledge-focused Recruiting nowThis study aims to collect tumor tissue and blood cells from people with advanced solid tumors to prepare for future CAR T-cell therapy. Researchers will analyze the cancer tissue to understand how tumors hide from the immune system and collect participants' own immune cells thro…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Sponsor: A2 Biotherapeutics Inc. • Aim: Knowledge-focused
Last updated Mar 19, 2026 14:55 UTC